bimagrumab glp 1 This New Drug Combo Beats GLP-1s Alone, Without One of the Biggest Side Effects semaglutide bimagrumab Antibody blockade of

According to Obesity Canada guidance: Adults (18+) are eligible for all GLP-1-based weight-loss medications Adolescents (12 years old) may be eligible for certain agents (e.g., liraglutide and semaglutide) depending on clinical context and approval status use in younger populations requires specialist involvement

Whether consumers are taking weight-loss drugs or not, the company says its new drink caters to anyone on a weight loss journey or looking to maintain or build muscle

Clinical studies have shown that this higher dose leads to greater weight loss compared to the doses used for diabetes management

Policy Revisions: Insurers may need to reassess coverage policies, potentially limiting access to these drugs for non-diabetic patients to curb misuse